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Our objective was to evaluate the benefit of early treatment of influenza illness using oral
oseltamivir. This open-label, multicentre international study investigated the relationship
between the interval from illness onset to first dose (time-to-treatment) and illness duration in
the intent-to-treat infected population using accelerated failure time (AFT) modelling. A total of
1426 patients (12–70 years) presenting within 48 h of the onset of influenza symptoms were
treated with oseltamivir 75 mg twice a day for 5 days during the 1999–2000 influenza season; 958
(67%) had laboratory-confirmed influenza virus infection. Earlier intervention was associated
with shorter illness duration (P < 0.0001). Initiation of therapy within the first 12 h after fever onset
reduced the total median illness duration by 74.6 h (3.1 days; 41%) more than intervention at 48 h.
Intermediate interventions reduced the illness proportionately compared with 48 h. In addition,
the earlier administration of oseltamivir further reduced the duration of fever, severity of
symptoms and the times to return to baseline activity and health scores. Oseltamivir was well
tolerated. The most common adverse events were nausea and vomiting, which were transient
and generally occurred only with first dosing. When oseltamivir was taken with food, the toler-
ability was enhanced. The overall discontinuation rate was low (1.8%). In conclusion, the
IMPACT study demonstrated that earlier initiation of oral oseltamivir therapy increased its
therapeutic effects, which were seen at every time point of intervention and were progressive.
Thus, early presentation, diagnosis and treatment of patients with influenza maximized the
benefits of oseltamivir therapy.
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Introduction
Annual influenza outbreaks lasting for 6–8 weeks result in
illness in an average of 10% of the population.1 Influenza
disrupts the normal activities of individuals and, because of
the large number of people incapacitated by the illness, results
in a considerable burden to society.2,3 Increases of up to five-
fold in consultations for influenza-like illness in general
practice intensifies pressure on primary healthcare services.4
There is a need for effective and well-tolerated treatments
that can reduce the impact of influenza on the individual and
society. Oseltamivir is the oral prodrug of oseltamivir car-
boxylate, a potent inhibitor of influenza A and B viral
neuraminidase. Oseltamivir is well tolerated and effective for
the treatment of acute influenza in previously healthy
adults.5,6 In influenza-infected patients treated within 36 h of
symptom onset, oseltamivir reduced the duration of clinical
illness by 30% (P < 0.001), when compared with symptom-
atic treatment alone.5
The pathogenesis of influenza illness suggests that inhibit-
ing viral replication as early as possible after infection will
reduce the duration and intensity of symptoms. In the study of
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Nicholson et al.,6 patients starting oseltamivir within 24 h of
symptom onset had a 37% reduction in illness duration
compared with placebo. Studies with the inhaled influenza
neuraminidase inhibitor zanamivir have also suggested the
additional benefit of earlier treatment.7,8 These findings are
consistent with increased treatment benefits that result from
early antiviral treatment of other viral diseases.9,10
The IMPACT (IMmediate Possibility to ACcess oseltami-
vir Treatment) study investigated the relationship between the
time to intervention and duration of illness as a primary end-
point, plus other parameters of illness, by treating with oral
oseltamivir as early as possible after the onset of influenza
symptoms.
Materials and methods
This was a prospective, open-label, exploratory, multicentre
international study conducted during the influenza season
1999–2000. During local influenza outbreaks, subjects aged
≥13–70 years presenting within 48 h of the sudden onset of
fever (≥37.8°C, ≥100°F) with at least two of the following
symptoms: cough, sore throat, coryza, myalgia, headache,
fatigue and chills/sweats were enrolled and received oral
oseltamivir 75 mg twice a day for 5 days. Volunteers were
advised to take the study medication with a meal or snack, and
ingestion of the first dose was observed directly and the time
recorded. Those with uncontrolled chronic medical disorders
were excluded as were women who were pregnant, lactating
or not using a reliable method of contraception. Individuals
who had HIV infection, a transplant or a clinically relevant
history of abuse of alcohol or other drugs were excluded. Sub-
jects who had experienced an acute upper respiratory tract
infection (URTI), otitis media, bronchitis or sinusitis or who
had been treated with an antiviral drug, systemic steroids or
immunosuppressants within 2 weeks of the study start were
also excluded. Influenza infection was confirmed by virus
recovery from nose or throat swabs taken pre-dose and on
day 3 (in selected centres only), and/or a ≥four-fold rise in
serum antibody titres to influenza virus. Nose and throat
swabs were transported to country-specific virology laborat-
ories either in chilled viral transport medium within 72 h or in
ambient conditions within 24 h of collection from the patient.
The swabs were eluted and inoculated onto Madin–Darby
canine kidney (MDCK) cell monolayers and incubated for
up to 7 days. Cell-associated influenza A or B viruses were
identified using immunofluorescent antibody techniques or
the haemadsorption test.
Baseline and day 21 sera were assayed together by meas-
urement of the haemagglutination-inhibition (HAI) antibody
or complement fixation test (CFT) antibody. The following
antigens were used for the majority of HAI assays: A/Bayern/
7/95 (H1N1), A/Sydney/5/97 (H3N2), B/Yamanashi/66/98;
the antigens used for CFTs were influenza A and B nucleo-
capsid.
Temperature and symptom scores were recorded twice
daily and a health scale questionnaire was answered daily for
21 days after the start of the study.
The primary endpoint was duration of illness as a function
of time to the first treatment dose, calculated from the time of
onset of fever (defined as the earliest time that the patient
either measured an elevated temperature or felt feverish) in
the laboratory-confirmed, influenza virus-infected population.
The duration of illness was defined as the time from symptom
onset to alleviation of all symptoms. Duration of illness was
measured from the onset of fever or when the patient felt
feverish until all symptoms were scored as mild or absent and
remained so for at least 24 h. Other endpoints included the
severity of the influenza illness by measurement of area under
the curve of total symptom scores, the times to resolution of
fever (assessed as the time to return to an afebrile state, i.e. a
temperature of ≤37.2°C), and return to baseline health and
activity scores. Adverse events were recorded up to study
day 21 (±4) and graded on a four-point scale (mild, moderate,
severe, life threatening).
The study was conducted in accordance with the principles
of the Declaration of Helsinki (amended) or with the laws
and regulations of the country in which the research was
conducted, whichever afforded the greater protection to the
individual. The protocols were approved by local or regional
ethics committees prior to implementation and all partici-
pants gave written informed consent before enrolment.
Analysis of data
To determine the added value of early intervention, the rela-
tionship between time to treatment and illness duration from
fever onset was analysed. The results were compared descript-
ively by time-to-treatment groups and also by accelerated
failure time (AFT) modelling on the actual data collected.11
The LIFEREG procedure in SAS (version 6.12) was used to
perform the AFT analysis, in a Unix environment. Estimates
were produced on the natural log scale, but were back-
transformed for presentation in all summary tables. The error
structure was modelled using the log-normal distribution, and
for all best fit models, normal probability plots of the residuals
were produced and examined for indications of lack-of-fit.
The median times of illness duration from illness onset are
also presented for time-to-treatment groups together with
95% confidence intervals.
Kaplan–Meier curves of the duration of illness data were
constructed for each time-to-treatment group in order to
estimate the median duration of illness and associated 95%
confidence interval along with other summary statistics.
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Results
A total of 1428 patients entered the study. Of these, 1426 re-
ceived study treatment and comprise the intent-to-treat (ITT)
safety population (Table 1). Two 12-year-old patients, who
deviated from the age inclusion criteria, were included in the
ITT population. The intent-to-treat infected (ITTI) popula-
tion consisted of the 958 (67%) subjects with laboratory-
confirmed influenza, 955 of whom received study medication
and provided data permitting calculation of the clinical
endpoints. There were no major differences in infection rates
between the time windows. Of the ITTI population, 140
(15%) subjects entered the study within 6 h of symptom onset,
240 (25%) within the first 12 h and 573 (60%) within 24 h.
There was a correlation between the time of intervention
after symptom onset and the illness duration, such that the
duration of illness was shorter the earlier treatment began
(Table 2). AFT modelling of the data confirmed that earlier
intervention was strongly associated with shorter illness
duration (P < 0.0001) (Table 3 and Figure 1). Intervention
within the first 12 h after fever onset reduced the median ill-
ness duration by 3.1 days more than if intervention was
delayed until 48 h (Figure 2). For every 6 h earlier that
oseltamivir was initiated, the predicted median illness dura-
tion was shortened by an acceleration factor of 1.09 (8%).
This corresponded to a benefit of ∼10 h (range 8–15) shorter
duration of illness for every 6 h earlier that treatment was initi-
ated. The outcomes based on the absolute time-to-treatment
group data and those produced by the use of AFT modelling
results were highly comparable.
As well as the additional benefit of early administration
on illness duration, benefits were also seen in other efficacy
endpoints. Earlier intervention was strongly associated with
a shorter time to return to normal health (P = 0.0001) and
baseline activity (P = 0.0001) (Figure 4). Earlier intervention
also reduced the fever duration (P = 0.0115) (Figure 4) and
severity of illness (P = 0.0023) (Figure 3). The acceleration
factors for these parameters were 1.05, 1.07, 1.12 and 1.03,
respectively. Approximately 90% of all influenza-infected
Table 1. Summary of the demographics of the safety 
population
Oseltamivir 75 mg twice 
a day (n = 1426)
Female, n (%) 716 (50%)
Median age (range; years) 40.0 (12–70)
Influenza virus infected, n (%) 958 (67%)
type A 944 (66%)
type B 6 (0%)
type A and B 8 (1%)
unknown 26 (2%)
Influenza vaccinated, n (%) 121 (8%)
Table 2. Duration of illness observed in the intent-to-treat infected population (n = 955) per time-to-treatment group in patients 
treated with oseltamivir 75 mg twice daily for 5 days 
aThe time from the start of the illness to alleviation of all symptoms.
Duration of illness (h) between onset of symptoms and treatment start
0–6 (n = 140) >6–12 (n = 100) >12–24 (n = 332) >24–36 (n = 258) >36–48 (n = 125)
Median duration (h)a (95% CI) 81.8 (70.7–105.5) 110.2 (93.0–123.5) 111.1 (98.5–122) 127.8 (111.8–151.5) 180.0 (146.7–202.8)
Table 3. Duration of illness predicted by the AFT modela in patients treated with oseltamivir 75 mg twice daily for 5 days 
aModel contains sex, age, baseline total symptom score, vaccination status time-to-treatment, baseline total symptom score time-to-treatment interactions.
bCompared with initiation of therapy at 48 h after start of illness. 
NA, not applicable; CI, confidence interval.
Time (h) from start of illness to treatment
0 6 12 24 36 48
Predicted median illness duration (h) 90.7 98.9 108 128.7 153.3 182.6
Reduction in illness duration (h)b 
(95% CI)
91.9 
(78.4–107.7)
83.6 
(72.2–96.8)
74.6 
 (65.0–85.6)
53.9 
 (47.2–61.5)
29.3 
 (25.3–33.9)
NA
Acceleration factorb 2.01 1.85 1.69 1.42 1.19 NA
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patients treated with oseltamivir had a reduction of fever,
<37.8°C, within 36 h of taking their first dose.
The duration of illness was seemingly shorter when inter-
vention occurred earlier in patients who were not infected
with influenza and treated with oseltamivir, but this was not
statistically significant (P = 0.3783) (Table 4). Thus, no thera-
peutic benefit was demonstrable as a result of oseltamivir
treatment in non-influenza virus-infected patients.
Oseltamivir was well tolerated. The incidence of adverse
event-related drug withdrawal was low, 25/1426 (1.8%), and
was similar to the number of patients who withdrew for
non-safety reasons (n = 21/1426, 1%). Most adverse events
were mild or moderate in severity. The most common adverse
events were gastrointestinal, mainly nausea (194/1426, 13.6%)
and vomiting (160/1426, 11.2%), which resolved with con-
tinued dosing; only 12 subjects (<1%) withdrew as a conse-
quence of these effects. The majority of these events occurred
between the first and second dose (∼70%). The incidence
of nausea was further reduced when the first dose was taken
with food (8.6%) compared with no food (13.6%, P = 0.009).
The overall incidence of vomiting was higher in patients with
influenza infection (9.9%) than in those without (6%,
P = 0.012).
Discussion
The IMPACT study, designed to investigate the relationship
of time-to-treatment with the illness duration and other
efficacy parameters, has confirmed that greater and incre-
mental benefits can be gained from treating influenza as soon
as possible after the appearance of symptoms. The study
design was predicated on knowledge that influenza illness
is associated with virus replication in the respiratory tract
that peaks 24–72 h after illness onset.12 Thus, drugs like
oseltamivir that would ameliorate illness solely by inhibiting
virus replication must be administered in the first 48–72 h of
illness, and preferably as early as possible. Early intervention
was shown to be strongly associated with a shorter duration
and a reduced severity of illness, a faster resolution of fever
and a faster return to normal health and activity. For the
primary endpoint, the data demonstrated that the total dura-
tion of illness could be halved if influenza patients were
treated early compared with intervention at 48 h. These data
complement the results from an earlier study with oseltamivir
in which subjects who started active treatment within 24 h of
Figure 1. The duration of influenza illness is shorter the earlier that
oseltamivir treatment 75 mg twice a day for 5 days is initiated (intent-to-
treat infected population).
Figure 2. The reduction in days of illness duration with earlier treat-
ment with oseltamivir 75 mg twice a day in comparison with delayed
treatment at 48 h (intent-to-treat infected population). The data are
median and 95% CI.
Figure 3. The reduction in total symptom score AUC with earlier treat-
ment with oseltamivir 75 mg twice a day in comparison with delayed
treatment at 48 h. The data are median and 95% CI.
Figure 4. The median reduction in days of impaired activity and health
and duration of fever with earlier treatment with oseltamivir 75 mg twice
a day in comparison with delayed treatment at 48 h (intent-to-treat
infected population).
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symptom onset had a 37% reduction in illness duration
compared with 25% in those who initiated therapy within 36 h
after onset of illness.6
This is the first report to describe the mathematical
relationship between illness duration and time to effective
antiviral intervention. The results based on the observed
time-to-treatment group data and those produced by AFT
modelling were highly comparable. The time-to-treatment
group data consisted of results for all subjects recruited within
specified mean 6 or 12 h windows, whereas AFT modelling
permitted us to predict the effect of intervention at any time as
well as the results of extrapolation to the limits of time stud-
ied. The observed effects and the values predicted by AFT
modelling were somewhat different even though they were
both derived from analysis of the study database.
The absence of a concurrent control group treated with
placebo in this study might raise the question of whether
the beneficial effects of early initiation of oseltamivir plus
symptomatic therapy in persons with influenza illness were
due to early initiation of symptomatic therapy alone. This is
unlikely given the previous observation in persons with
laboratory-confirmed influenza who were treated with the
same symptomatic therapy plus placebo,6 in whom no differ-
ence was observed in the median duration of illness between
those persons treated at <36 h and those in whom therapy was
initiated within 24 h of illness onset.
The study confirmed that physicians can accurately dia-
gnose influenza in patients reporting soon after fever onset by
use of a clinical case definition and knowledge that influenza
virus is circulating within the community. There were no
major differences in the sensitivity of the clinical diagnosis
between the treatment time windows, and the 67% infection
rate was similar to that found in previous placebo-controlled
treatment studies with oseltamivir.5,6 The study also con-
firmed that influenza presents with characteristic sudden
identifiable and severe symptom onset,13 only 2/958 patients
having presented with mild symptoms in this study. Educa-
tion of potential volunteers about symptoms of influenza
illness made possible self-referral for diagnosis and the
implementation of antiviral therapy.
The proportion of individuals with influenza who receive
some form of drug treatment is 59%. Antibiotics are the most
frequently prescribed drugs (45%), followed by antipyretics/
analgesics (22.5%).3 Antibiotics are likely to be prescribed to
patients with influenza in all age groups.14,15 Inappropriate
antibiotic treatment provides no medical benefit and increases
the risk of antibacterial resistance.15 The results of this study
confirm that oseltamivir therapy would be more logical than
antibiotics for patients with uncomplicated influenza.
Translating the results of this study into clinical practice
will be challenging, but, it is argued, clinically important.
Strategies to do so must provide early diagnosis and access to
oseltamivir therapy without markedly increasing the work-
load for practitioners in the influenza season. This study has
demonstrated that early presentation is possible by public
education of influenza symptom characteristics, as approxi-
mately two-thirds of those who were infected presented to
their general practitioners within 24 h of symptom onset, and
a quarter within 12 h. One solution may lie in application of
the UK Department of Health guidelines to implement the
NICE recommendations for another neuraminidase inhibitor
drug, zanamivir.16 Telephone triage and walk-in centres for
specific patient groups organized by practice nurses or other
health professionals, e.g. community pharmacists, working to
a protocol of standard diagnostic questions will help address
the issues of overburdened GPs and facilitate timely initiation
of treatment.
The overall incidence and pattern of adverse events were
similar to those reported in previous studies.5,6 Nausea was
significantly reduced by taking the first dose of oseltamivir
with food, suggesting that the mechanism of action may be at
the local gastric level. The proportion of patients who discon-
tinued drug because of gastrointestinal events was small and
similar to previous studies, due to the fact that the majority of
these events were of isolated occurrence after the first dose
and did not persist with continued dosing.
Conclusion
The IMPACT study adds to our understanding of the benefits
of oral oseltamivir therapy of influenza, by demonstrating
that earlier intervention enhances treatment effects. Early
intervention can reduce the total illness duration by up to one
Table 4. Duration of illness observed in the population without laboratory-confirmed influenza (n = 461) treated with 
oseltamivir 75 mg twice daily for 5 days per time-to-treatment group
CI, confidence interval.
Duration of illness (h) between onset of symptoms and treatment start
0–6 (n = 99) >6–12 (n = 70) >12–24 (n = 167) >24–36 (n = 93) >36–48 (n = 32)
Median duration (h) 83.0 77.4 112.1 124.5 196.0
(95% CI) (75.5–107.0) (64.8–105.3)  (97.0–133.9) (115.5–152.0) (133.8–250.8)
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half compared with later treatment, resulting in faster recov-
ery and resumption of normal activities. The IMPACT study
demonstrated the value of early presentation, and diagnosis
of patients with influenza illness and their treatment with
oseltamivir.
Acknowledgements
We thank all participating physicians, study investigators and
the Roche study management team (Charlotte Harding Rains,
Penny Kirkwood, Kevin Drabble, David Merritt, Laurence
Bourdeau, Diane Ginn and Shelina Rajan) who made this
project possible. The authors gratefully acknowledge
Stephen Pawsey (clinical science), Jennifer Gilbride, Nelson
Kinnersley, Tracey Mills and Paul Mahoney (biostatistics) at
Roche Global Development. We would also like to acknow-
ledge the contribution of Dr Torsten Hoof who helped with
the design of this study. This study was financially supported
by F. Hoffmann-La Roche Ltd.
Study investigators: Belgium: Didier, Vanret – Namur; Frans,
Pardinaens – Antwerpen; Didier, Giet – Liege; Bernard, Clar-
ysse – West-Vlaaderen; Jacques, Saintpo – Hainaut; Frank,
Decoutere – Limburg; Rodolphe, Liagre – Oost-Vlaanderen;
Noel, Provoost – Vlaams Brabant; Canada: Dr G. Acyuthan –
Regina; Dr Marc Afilalo – Montreal; Dr Gordon Arbess
– Toronto; Dr Laurie Breger – Montreal; Dr I. Campbell –
Montreal; Dr David Carswell – Harrow; Dr Howard Conter –
Halifax; Dr Percy Crocker– St John’s; Dr Francisco Diaz-
Mitoma – Ottawa; Dr Anthony D’Urzo – Toronto; Dr G.W.
Hammond – Winnipeg; Dr Brian R. Holroyd, – Edmonton;
Dr Allan Kelley – Edmonton; Dr Gerald Lazarenko – Calgary;
Dr P.H. Orr – Winnipeg; Dr Jean-Pascal Ouellet – Sher-
brooke; Dr Plyush Patel – Toronto; Dr Daniel Shu – Vancou-
ver; Dr J.N. Simonsen – Winnipeg; Dr Guy Stiver – Montreal;
Dr Sylvie Trottier – Quebec City; Dr Paul Whitsitt – Oshawa;
Denmark: Bente, Klarland – Copenhagen; Ronald, Dahl –
Aarhus; Jacobsen – Vig; Laybourn – Copenhagen; Schelde –
Vig; Wilstrup – Soro; Pertti, Himanen – Turku; Timo, Kaitilia
– Lappeenranta; Leena, Kiiski – Kuopio; Perti, Kivi – Tam-
pere; Jamo, Koski – Jyvaskylan; Merja, Pitkanen – Helsinki;
Arto, Strandberg – Helsinki; Timo, Veskiari – Tampere;
France: Dr Alain Campagne – Tours; Dr Gilles Grandmottet –
Besancon; Dr Michael Gregoire – Tallard; Dr Dominique
Lejay – Vieux Conde; Dr Charles Mercier, Henri – Montagne;
Dr Gerald Mongin – Mont Pellier; Dr Simon Musso – Eaunes;
Dr Francois Spilthooren – Evreux; Dr Richard Josse –
Bordeaux; Dr Bruno Pascal – Toulon; Dr Jean-Loup Rey –
Armees; Dr Jean-Louis Soares – Armees; Germany: Dr Flob-
dorf – Duren; Dr Barghoom – Dormage; Dr Gessert – Rothen-
burg; Dr Schlauch – Lochham; Dr Adler – Ludwigshafen;
Dr Ludke – Freiburg; Iceland: Gunnar, B. Gunnarsson –
Reykjavik; Vilhjalmur, Ari Arason – Hafnarfjordur; Jon,
Stiener Jonsson – Gardabaer; Ireland: Dr Tom Finnegan –
Dublin; Dr Brian O’Doherty – Donaghmeade; Dr Niall Moore
– Dublin; Dr Liam Lynch – Dublin; Dr Philip O’Connell –
Dublin; Dr Alan Byrne – Dublin; Dr William Kavanagh –
Dublin; Dr Tim Gleeson – Dublin; Israel: Prof Shai Ashkenzi
– Petach-Tikva; Dr Efrat Harlev – Shoam; Prof Ethan Rubin-
stein – Givataeem; Dr Aya Shelem – Hedera; Dr Tessa
Shelouche – Hedera; Dr Dorit Wolf – Natania; Dr Moshe
Zlotnik – Ashkelon; Dr Bibiana Chazan – Tiberia; Dr Nava
Gasper – Ofakim; Dr David Hassin – Hedera; Dr Nir Heil-
zenrat – Kiryat-Gat; Dr Doron Hemoni – Hedera; Dr Liora
Ben, Nitzan Masika – Petach Tikva; Dr Raul Raz – Afula; Dr
Moshe Torem – Afula; Dr Tsvika Weiss – Herzelia; Dr Yoran
Menda – Herzelia; Dr Akram Abdful – Ofakim; Dr Bibiana
Chazan – Tiberia; Dr Gay Nir – Afula; Dr Avraham Borer –
Ofakim; Dr Bat-Sheva Gottersman – Kfar-Saba; Dr Yova
Helman – Natania; Dr Oma Ofir – Afula; Prof Fransinsc
Schlaeffer – Beer-Sheva A; Dr David Gabay – Rishon Lezion;
Dr Oren Avraham – Natania; Dr Cama Sulliman – Tiberia;
Italy: Prof Pietro Crovari – Genova; Netherlands: Dr G.J.M.
Van Doesburg – Lichtenvoorde; Luiten – Den Haag; Dr
R.G.G. Groot – Arnemuiden; Dr P.H.L. Hofstede – Giesbeek;
Dr F.B. Naber – Heemskerk; Dr J. Veerman – Nijverdal;
Norway: Sigbjorn, Elle – Elverum; Mikkel, Mundal – Oslo;
Niels-Erik, Landmark – Sandvika; Sjur Rod-Larsen – Asgard-
strand; Pal, Vik – Sandvika; Kristian, Furuseth – Jessheim;
Sigve, Tonstad – Oslo; Aage, Bjertnaes – Trondheim; Sweden:
Dr Stig Cronberg – Maimo; Dr Per Forsberg – Vaxjo ; Dr
Peter Holgersson – Karlskrona; Dr Bo Claesson – Goteborg;
Dr Mikael Mullart – Sundsbruk; Dr Eva Gutniak – Vael-
lingsby; Switzerland: Claude, Breitenstien – Liestal; Roland,
Seitz – Margrethen; Urs, Beat Goflin – Binningen; Thomas,
Aeschbach – Lausanne; Eric, Jensen – Bern; Blaise, Genfron
– Lausanne; UK: Hall, Tim – Plymouth; Middleton – Fowey;
Ritchie – Peterhead; Haworth – Blackpool; Doel – Cleveleys;
Newby – Cambridgeshire; Rogers, D. – Edgbaston; Wallace,
P. – Cheadle; Anderson, D. – Bristol; Crawford, A. – Win-
chester; Dove, N. – Harrow; Lynch, H. – Bolton; Finlay, M. –
Rochdale; Gilfeather, B. – Windsor; Arora, S. B. – London;
Jones, G. – Canterbury; Moseley, D. – Sheffield; Muir, W. –
Nottingham; Quinn, Leslie – Glasgow; Richardson, D. –
Dorset.
References
1. Nichol, K. L., Lind, A., Margolis, K. L., Murdoch, M., McFadden,
R., Hauge, M. et al. (1995). The effectiveness of vaccination against
influenza in healthy, working adults. New England Journal of
Medicine 333, 889–93.
2. Monto, A. S. (1999). Individual and community impact of
influenza. Pharmacoeconomics 16, Suppl. 1, 1–6.
3. Meier, C. R., Napalkov, P. N., Wegmüller, Y., Jefferson, T. &
Jick, H. (2000). Population-based study on incidence, risk factors,
clinical complications, and drug utilisation associated with influenza
Early treatment benefits of oseltamivir
129
in the United Kingdom. European Journal of Clinical Microbiology
and Infectious Diseases 19, 834–42.
4. Fleming, D. M., Chackraverty, P., Sadler C. & Litton, P. (1995).
Combined clinical and virological surveillance of influenza in winters
of 1992 and 1993–4. British Medical Journal 311, 290–1.
5. Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R.,
Bettis, R., Riff, D. et al. (2000). Efficacy and safety of the oral
neuraminidase inhibitor oseltamivir in treating acute influenza: a
randomized, controlled trial. Journal of the American Medical
Association 283, 1016–24.
6. Nicholson, K. G., Aoki, F. Y., Osterhaus, A. D. M. E., Trottier, S.,
Carewicz, O., Mercier, C. H. et al. (2000). Efficacy and safety of
oseltamivir in treatment of acute influenza: a randomised controlled
trial. Lancet 355, 1845–50.
7. Hayden, F. G., Treanor, J. J., Betts, R. F., Lobo, M., Esinhart,
J. D. & Hussey, E. K. (1996). Safety and efficacy of the neura-
minidase inhibitor GG167 in experimental human influenza. Journal
of the American Medical Association 275, 295–9.
8. Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming,
D. M., Aoki, F. Y., Nicholson, K. G. et al. (1997). Efficacy and safety
of the neuraminidase inhibitor zanamivir in the treatment of
influenza virus infections. New England Journal of Medicine 337,
874–80.
9. Ogilvie, M. M. (1998). Antiviral prophylaxis and treatment in
chickenpox. A review prepared for the UK Advisory Group on
Chickenpox on behalf of the British Society for the Study of Infec-
tion. Journal of Infection 36, Suppl. 1, 31–8.
10. Wood, M. J., Shukla, S., Fiddian, A. P. & Crooks, R. J. (1998).
Treatment of acute herpes zoster: effect of early (< 48 h) versus late
(48–72 h) therapy with acyclovir and valaciclovir on prolonged pain.
Journal of Infectious Diseases 178, Suppl. 1, S81–4.
11. Collet, D. (1997). Modelling Survival Data in Medical Research.
pp. 204–18. Chapman & Hall, London, UK.
12. Murphy, B. R., Baron, S., Chalhub, E. G., Uhlendorf, C. P. &
Chanock, R. M. (1973). Temperature-sensitive mutants of influenza
virus. IV. Induction of interferon in the nasopharynx by wild-type and
a temperature-sensitive recombinant virus. Journal of Infectious
Diseases 128, 488–93.
13. Snacken, R. & Influenza Diagnosis Working Party. (2000).
Managing influenza in primary care; a practical guide to clinical
diagnosis. Disease Management and Health Outcomes 8, 79–85.
14. Neuzil, K. M., Mellen, B. G., Wright, P. F., Mitchel, E. F. &
Griffin, M. R. (2000). The effect of influenza on hospitalizations, out-
patient visits, and courses of antibiotics in children. New England
Journal of Medicine 342, 225–31.
15. Ochoa, C., Eiros, J. M., Inglada, L., Vallano, A., Guerra, L. & the
Spanish Study Group on Antibiotic Treatments. (2000). Assessment
of antibiotic prescription in acute respiratory infections in adults.
Journal of Infection 41, 73–83.
16. Department of Health, National Assembly of Wales. (2000).
NICE Guidance on the Use of Zanamivir (Relenza): Implementation
Guidance for NHS. 21st Nov 2000. [Online.] http://www.doh.gov.uk/
zanamivirguidance (1 May 2001, date last accessed).

